Back to Journals » Therapeutics and Clinical Risk Management » Volume 5

A new extended release formulation (OROS®) of hydromorphone in the management of pain

Authors Weinstein S

Published 9 December 2008 Volume 2009:5 Pages 75—80

DOI https://doi.org/10.2147/TCRM.S1124


Sharon M Weinstein

University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, USA

Abstract: Opioid analgesics are essential in the treatment of moderate to severe cancer-related pain. Opioids are also recognized as important in the management of other severe, persistent refractory painful conditions, such as sickle cell disease and arthritis. In the clinical practice of pain management, stable opioid dosing generally depends on achieving maximal analgesia with tolerable side effects typical of opioid analgesics. There is a wide interindividual variability of responsiveness to exogenous opioids both in terms of analgesic efficacy and side effects. Optimizing pain management for the individual patient may require sequential trials of opioid medications until the regimen with the most favorable therapeutic ratio of efficacy to side effects is determined.

Keywords: analgesics, opioid, hydromorphone, OROS®, extended-release

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]